Barchart6d agoneutral
Why DataMEDS’ Acquisition Does Not Seem to Be Very Bullish for MEDS Stock at This PointThe low purchase price of Helomics and low revenue suggest that the acquisition is not that promising for DataMEDS AI.
Notícias
Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
135last 24h
869last 7d
144● bullish (7d)
99● bearish (7d)
214publishers
24/7 Wall St.44d agobullish
The Biggest IPO of the Year Is Targeted in the Next 60 Days. Why One Unexpected Industry Could Rally Before Then (Hint: It’s Not Tech)Anthropic is racing toward a public debut in September with a healthcare AI pitch that could ignite a sector most investors are not watching. Five biotech names are already moving, and one has climbed nearly 400% in the past year alone.
GuruFocus.com49d agobullish
Schrodinger Inc (SDGR) (Q2 2026) Earnings Call Highlights: ACV Surges 27% on Bunsen Launch and ...Schrodinger Inc (SDGR) reports robust Q2 2026 with record ACV growth, strategic AI advancements, and raised full-year drug discovery guidance despite margin pressures from hosted transition.
MarketBeat49d agoneutral
Schrodinger Q2 Earnings Call HighlightsSchrodinger (NASDAQ:SDGR) said second-quarter annual contract value growth accelerated as demand broadened across large pharmaceutical customers, biotechnology companies and materials-science customers, while the company launched early access for Bunsen, its agentic AI co-scientist. Second-quarter
Moby141d agoneutral
Schrödinger, Inc. Q1 2026 Earnings Call SummaryMoby summary of Schrödinger, Inc.'s Q1 2026 earnings call
MarketBeat141d agoneutral
Schrodinger Q1 Earnings Call HighlightsSchrodinger (NASDAQ:SDGR) reported first-quarter 2026 results and highlighted progress in its transition to hosted software licensing, growth in annual contract value (ACV), and recent business development activity tied to its drug discovery collaborations. First-quarter metrics and hosted transiti